Performance of EGFR mutant-specific antibodies in different cytological preparations: A validation study

Cytopathology

Volumn 26, Issue 2, 2015, Pages 99-105

  Bellevicine, C ^a   Bianco, A ^a   Malapelle, U ^a   De Luca, C ^a   Vigliar, E ^a   Cacciola, N A ^a   Pallante, P ^a   Troncone, G ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

EGFR mutations; Immunocytochemistry; Molecular biology; Mutation specific antibodies; Non small cell lung cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY;

ARTICLE; CELL MUTANT; CONTROLLED STUDY; CYTOLOGY; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MUTATIONAL ANALYSIS; PERFORMANCE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; STAINING; VALIDATION STUDY; CARCINOMA, NON-SMALL-CELL LUNG; EXON; GENETICS; IMMUNOLOGY; LUNG NEOPLASMS; MUTATION; PROCEDURES; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; EXONS; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84925302344     PISSN: 09565507     EISSN: 13652303     Source Type: Journal    
DOI: 10.1111/cyt.12155     Document Type: Article

References (25)

1. Malapelle U, De Rosa N, Rocco D, et al. EGFR and KRAS mutations detection on lung cancer liquid-based cytology: a pilot study. J Clin Pathol 2012;65:87-91.
2. Malapelle U, De Rosa N, Bellevicine C, et al. EGFR mutations detection on liquid-based cytology: is microscopy still necessary? J Clin Pathol 2012;65:561-4.
3. Malapelle U, Bellevicine C, De Luca C, et al. EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung carcinoma patients. Cancer Cytopathol 2013;121:552-60.
4. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med 2013;137:828-60.
5. Yu J, Kane S, Wu J, et al. Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res 2009;15:3023-8.
6. Von Deimling A, Sahm F, Capper D. Mutation specific antibodies: tool or dinosaur? Oncotarget 2012;3:907-8.
7. Tsai T-H, Wu S-G, Chang Y-L, et al. Effusion immunocytochemistry as an alternative approach for the selection of first-line targeted therapy in advanced lung adenocarcinoma. J Thorac Oncol 2012;7:993-1000.
8. Jiang G, Fan C, Zhang X, et al. Ascertaining an appropriate diagnostic algorithm using EGFR mutation-specific antibodies to detect EGFR status in non-small-cell lung cancer. PLoS ONE 2013;8:e59183.
9. Hasanovic A, Ang D, Moreira AL, Zakowski MF. Use of mutation specific antibodies to detect EGFR status in small biopsy and cytology specimens of lung adenocarcinoma. Lung Cancer 2012;77:299-305.
10. Kawahara A, Azuma K, Sumi A, et al. Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry. Lung Cancer 2011;74:35-40.
11. Kurtycz DF, Logrono R, Leopando M, Slattery A, Inhorn SL. Immunocytochemistry controls using cell culture. Diagn Cytopathol 1997;17:74-9.
12. Wiatrowska BA, Berner A, Torlakovic G et al. Cultured anaplastic cell lines as immunocytochemistry controls: a comparison of ThinPrep-processed smears and conventional air-dried cytospins. Diagn Cytopathol 2001;25:303-8.
13. Kawahara A, Taira T, Abe H, et al. Fixation effect of SurePath preservative fluids using epidermal growth factor receptor mutation-specific antibodies for immunocytochemistry. Cancer Cytopathol 2013;122:145-52.
14. Simonetti S, Molina MA, Queralt C, et al. Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer. J Transl Med 2010;8:135.
15. Kawahara A, Yamamoto C, Nakashima K, et al. Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis. Clin Cancer Res 2010;16:3163-70.
16. Abele JS, Miller TR, King EB, Lowhagen T. Smearing techniques for the concentration of particles from fine needle aspiration biopsy. Diagn Cytopathol 1985;1:59-65.
17. Bellevicine C, Malapelle U, de Luca C, Iaccarino A, Troncone G. EGFR analysis: current evidence and future directions. Diagn Cytopathol 2014; doi: 10.1002/dc.23142 [Epub ahead of print].
18. Wu S-G, Chang Y-L, Lin J-W, et al. Including total EGFR staining in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response prediction. PLoS ONE 2011;6:e23303.
19. Cooper WA, Yu B, Yip PY, et al. EGFR mutant-specific immunohistochemistry has high specificity and sensitivity for detecting targeted activating EGFR mutations in lung adenocarcinoma. J Clin Pathol 2013;66:744-8.
20. Kato Y, Peled N, Wynes MW, et al. Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations. J Thorac Oncol 2010;5:1551-8.
21. Brevet M, Arcila M, Ladanyi M. Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. J Mol Diagn 2010;12:169-76.
22. Soh J, Okumura N, Lockwood WW, et al. Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. PLoS ONE 2009;4:e7464.
23. Isaksson S, Bendahl P-O, Salomonsson A, et al. Detecting EGFR alterations in clinical specimens-pitfalls and necessities. Virchows Arch 2013;463:755-64.
24. Zhao J, Wang X, Xue L, et al. The use of mutation-specific antibodies in predicting the effect of EGFR-TKIs in patients with non-small-cell lung cancer. J Cancer Res Clin Oncol 2014;140:849-57.
25. Colasacco C, Mount S, Leiman G. Documentation of immunocytochemistry controls in the cytopathologic literature: a meta-analysis of 100 journal articles. Diagn Cytopathol 2011;39:245-50.